Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $232,946.58 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 5,001 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total value of $232,946.58. Following the completion of the transaction, the chief executive officer owned 869,312 shares of the company’s stock, valued at $40,492,552.96. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Twist Bioscience Price Performance

TWST stock opened at $49.23 on Friday. The stock has a market capitalization of $3.02 billion, a price-to-earnings ratio of -38.46 and a beta of 2.24. The company has a quick ratio of 3.33, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $54.26. The stock’s fifty day simple moving average is $36.88 and its 200-day simple moving average is $32.02.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. The company’s quarterly revenue was up 16.9% compared to the same quarter last year. Equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Trading of Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares during the last quarter. D.A. Davidson & CO. grew its holdings in Twist Bioscience by 1.2% during the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after purchasing an additional 305 shares during the period. CWM LLC boosted its stake in shares of Twist Bioscience by 9.4% during the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after acquiring an additional 407 shares during the period. California State Teachers Retirement System boosted its position in Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after buying an additional 442 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Barclays increased their target price on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday. Stephens began coverage on shares of Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target for the company. Finally, Evercore boosted their price target on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Key Stories Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Management raised guidance and commentary pointed to stronger demand from AI-related customers, suggesting improving end‑market traction (though reporters flagged execution risk). Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
• Positive Sentiment: At least one analyst raised the price target sharply (20% boost to $48.35), signaling increased sell‑side bullishness that can support further upside and institutional interest. TWST price target increased by 20%
• Neutral Sentiment: Coverage pieces are reassessing valuation after the recent run‑up — useful for investors deciding whether the rally already embeds the guidance improvement or leaves room for more upside. Assessing Twist Bioscience Valuation
• Negative Sentiment: CEO Emily Leproust sold 5,001 shares at an average ~$46.58 (≈0.57% reduction); insider sales by the CEO can raise short‑term concern about insider conviction even if they are for diversification or routine tax/liquidity reasons. CEO sale filing
• Negative Sentiment: Other senior insiders sold this week (CAO Robert Werner sold 7,000 shares — a meaningful ~10.65% reduction in one filing — plus additional smaller sales; SVP Paula Green and insider Dennis Cho also sold). The cluster of senior‑level sales increases perceived insider pressure despite the positive guidance. CAO sale filing SVP sale filing Insider sale filing

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.